Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL

This prospective, randomized, controlled trial evaluates the efficacy and safety of a new targeted drug combined with chemotherapy versus standard chemotherapy alone. Eligible patients were randomized 1:1 to either the treatment or control group.

Trial Details

NCT ID
NCT07203352
Phase
PHASE3
Sponsor
Nanfang Hospital, Southern Medical University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • targeted drug
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • The subjects were diagnosed with acute T-lymphocytic leukemia (according to the 2016 WHO classification) based on their bone marrow pathology and h…
  • The subjects must have never received anti-leukemia treatment before;
  • Age ≥ 18 years old, gender not restricted;
  • The subjects' Eastern Cooperative Oncology Group (ECOG) performance status score is 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →